Lifeline Biotechnologies EBIT

As of the most recent data (June 2026), LLBO shows a EBIT of $-34K. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

The Healthcare sector average EBIT is about $22B. Lifeline Biotechnologies is at $-34K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how LLBO stacks up against individual peers as well.

Tracking LLBO's ebit over time shows whether Lifeline Biotechnologies is scaling, shrinking, or reshaping that part of the business. The current reading is $-34K Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Lifeline Biotechnologies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-34K) with ownership activity and broader fundamentals.

The Healthcare average EBIT is about $22B, while LLBO is at $-34K. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.